Pulse Biosciences, Inc. (FRA:6L8)

Market Cap	1.44B +39.1%
Revenue (ttm)	651.34K
Net Income	-64.67M
EPS	-0.96
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	20.60
Previous Close	21.00
Day's Range	20.20 - 20.60
52-Week Range	10.80 - 23.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled conso...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2014
• Employees: 116
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6L8

Financial Performance

Financial numbers in USD